

E&P HEALTHCARE CONFERENCE PRESENTATION

PERTH, Australia and SAN FRANCISCO, California – 12 September 2023

PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC's CEO, Dr Rohan Hockings, at the E&P Healthcare Conference, 12 September 2023.

About PYC Therapeutics

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood (RP11) into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit pyctx.com, or follow us on [LinkedIn](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

2. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA

info@pyctx.com



PYC
Therapeutics

Life-changing science

E&P healthcare conference

September 2023



Disclaimer



The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of

which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Executive Summary – PYC Therapeutics



A **clinical-stage** drug discovery & development company



Creating **first-in-class RNA drugs** for patients with **genetic diseases**



With a **multi-asset pipeline** - each program targeting commercially attractive markets (**\$1 to \$5 billion p.a. each**)



With **multiple major near-term catalysts** including human data generation every 12 months¹



Developing the class of drug with the **highest likelihood of success** in clinical trials²



3 key points for today:

- 1) Multiple assets
- 2) Immediate milestones
- 3) Higher probability of success




PYC's approach to drug development


differentiated by its drug delivery platform and the potency advantage this creates

The fundamental challenge for RNA drugs is adequate delivery to the target cell

PYC combines existing RNA drug design technology with its proprietary drug delivery platform to create potent and precise RNA therapeutics




PYC's drug delivery platform is used to assist the RNA drug reach its target inside the cell




PYC's delivery platform achieves ~100x the target engagement of the equivalent 'naked' RNA drug *in vivo*¹

PYC is progressing a pipeline of first-in-class drugs with disease-modifying potential into multi-billion dollar markets



3 critical features differentiate PYC's path to revenue



Are drugs for monogenic diseases really 5-8x more likely to succeed in the clinic?

How likely is a drug targeting a monogenic disease to succeed in the clinic?	Source
<u>6x more likely</u> than the industry average (of ~10%) with a 64% likelihood of successful marketing approval on commencement of Phase 1 studies	Alnylam – pipeline retrospective ¹
<u>Up to 8x more likely</u>	Atlas Ventures ²
<u>5x more likely</u>	UK Biobank ³

Non-clinical models provide early insight into clinical outcomes – particularly in monogenic diseases

“We need to understand as early as possible whether a drug candidate is safe and works in patients, not wait to find out in clinical trials which can be expensive and time-consuming”¹

Complexity of a living organism

1. Is the drug safe and well tolerated in NHPs?
2. Does it reach the target cell in NHPs?
3. Does it correct the gene expression deficit?
4. Does it rescue the disease phenotype?

Non-Human Primates (NHPs)



Complexity of the actual human disease


Patient-derived ‘retina-in-a-dish’



5. Is this drug safe and effective in humans?

The combination of these two models provides unique insight into the prospects of a successful path through the clinic

PYC expects 5 human data read-outs within the next 36 months



PYC's Board, Executive and Advisory teams



Alan Tribe
Chairman

Experience commercialising Australian technology in US markets, and managing and leading growth companies across technology, resources and retail



Dr Rohan Hockings
Chief Executive Officer

Dual-trained in medicine and law with experience across both disciplines in addition to roles in strategy consulting and private equity



Sri Mudumba
Chief Research & Development Officer

Over 20 years of experience developing drug delivery products utilising various therapeutic modalities and delivery vehicles from early research through to NDA



Andrew Taylor
Chief Financial Officer

Held senior finance positions in ASX listed organisations. Completed multiple capital markets and M&A transactions.



Paula Cunningham
Senior VP Preclinical R&D

Over 20 years research experience in molecular biology and immunology with expertise in assay development for drug candidate identification



Dr Michael Rosenblatt
Director

Former Senior Partner with Flagship Pioneering, previously EVP and Chief Medical Officer at Merck. Deep experience in leading numerous drug development programs, and guiding strategies at biopharma and academic institutions



Jason Haddock
Director

Over 20 years' experience in finance, operations and commercialisation of biotechnology companies including at Array BioPharma and Bristol Myers Squibb



Prof Ian Constable
Advisory board

Renowned Ophthalmologist for over 50 years. Founding Managing Director and now the Patron of the Lions Eye Institute Western Australia. Pioneered first in man gene therapy for macular degeneration



A/Prof Fred Chen
Advisory board

Ophthalmologist at Lions Eye Institute (LEI), Royal Perth Hospital and Perth Children's Hospital Western Australia. Performed over 800 vitrectomy surgeries. Lead Research Scientist LEI's Ocular Tissue Engineering Laboratory



Prof Sue Fletcher
Advisory Board

Leading global expert and pioneer in RNA therapeutics with over 30 years experience developing RNA drugs. Co-inventor of Exondys-51, Vyondys-53, and Amondys-45 and VP-001



PYC
Therapeutics



A **clinical-stage** biotechnology company



Dedicated to **changing the lives of patients** with genetic diseases



Generating critical **human data read-outs** every year from now on



For **first-in-class drug candidates** with **disease-modifying potential** and the **highest prospect of success in the clinic**¹



Targeting markets worth **\$1 to \$5 billion per annum**²

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: <https://doi.org/10.1101/2020.11.02.2022232>

² See market sizing calculations on page 6

